Lei Jianping on January 29
Aprinoia Therapeutics, a clinical-stage biopharmaceutical company, has submitted a prospectus to list on the NASDAQ in the United States.
Half-year revenue was $9.03 million
The English name "aprinoia" is a combination of the Latin word "apricum", which symbolizes sunlight, and the Greek suffix "noia", which means "mind".
Asahi Biotech develops novel** and precise diagnostic technologies for neurodegenerative diseases including Alzheimer's disease ("AD"), Parkinson's disease ("PD"), and certain rare dementia and movement disorders.
Asahi Biotech specializes in tau and synucleinopathies, which affect approximately 50 million and 10 million people worldwide, respectively, with cognitive or behavioral disorders caused by these two types of proteinopathies. They are responsible for the majority of cases of dementia and movement disorders and exacerbate psychological and socioeconomic problems, including the stress of prolonged care, inadequate nursing home allocation, and death without effective medications**.
In 2017, the U.S. Food and Drug Administration ("FDA") received Orphan Drug Designation for 18F-APN-1607 (INN:Florzolotau (18F)) as a diagnostic tracer for progressive supranuclear palsy ("PSP");
According to the prospectus, Xinxu Biotech's revenue in 2022 will be 39US$40,000, down 28% from US$550,000 in the same period last year; Operating loss was $28.26 million, compared to an operating loss of $23.89 in the year-ago quarter$70,000, an increase of 18%; Net loss was $28.23 million, compared to a net loss of $23.26 million in the year-ago quarter.
Asahi Biotech's revenue for the first half of 2023 was 903$40,000, compared to revenue of $29 in the year-ago quarter$50,000; The operating loss was 673$70,000, compared to an operating loss of $13.84 million in the same period last year; The net loss was 718$50,000, compared to a net loss of 1,367 in the same period last year$60,000.
A new CEO has just been appointed
In August 2023, the Board of Directors of Asahi Biotech appointed Mark SDr. Shearman is the Chief Executive Officer. Dr. Zhang Mingkui, the founder of Asahi, remains the Chairman of the Board and also serves as the Chief Operating Officer of Asahi Asia.
Dr. Shearman holds a Ph.D. in neuroscience and has extensive experience in pharmaceutical research, drug development, and strategic collaborations.
Prior to joining Singah, he worked at Editas Medicine, Applied Genetic Technologies Corporation, Merck KGAA and Merck & Coand has served as Chairman of the Scientific Advisory Board of Asahi since 2015.
The management team of Asahi Biotech also includes Dr. Brad N**ia, Chief Medical Officer, Brian Achenbach, CFO, Lana Gladstein, Ph.D., Group General Counsel and Chief Operating Officer, and the management team includes Dr. Paul Tempest, Head of Medicinal Chemistry, Dr. Lili Zhang, Head of Preclinical Development, Dr. Masatomi Miyamoto, Head of Asahi Tokyo, Japan, and Dr. Zichen Yan, M.D., Head of Sunrise China Suzhou. and Chen Zhiqiang, head of Xinxu China in Hong Kong.
In November 2021, Xinxu Biotech announced the completion of a $40 million Series C financing, which was not only supported by the original shareholders including KTB Network, IMM Private Equity and Taian Biotech, but also welcomed the participation of pharmaceutical companies and investment institutions such as Yantai Dongcheng Pharmaceutical Group and Suzhou Yuanfeng Capital Management***, a subsidiary of Suzhou Industrial Park.
Before the IPO, Ming-Kuei Jang held 87%, Dongcheng Pharma holds 204%, and Wealth Path Investments Limited holds 105%, and Daiwa Taiwan-Japan Biotech Fund holds 104%, KTB China Synergy Fund holds 91%, and Shangpharma Investment Group Limited holds 69%。
Lei Di was founded by ** Lei Jianping, if ** please in**.